Evaluation of the effect of vitamin C on flu-like syndrome in multiple sclerosis patients receiving beta-interferon

Evaluation of the effect of vitamin C on frequency and severity of flu-like syndrome in multiple sclerosis patients receiving beta-interferon

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211122053145N2

Enrollment

100

Registered

2023-06-17

Start date

2023-04-30

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Daily intake of one 250 mg vitamin C chewable tablet made by Osve company for three months. Intervention 2: Control group: Daily intake of a placebo pill similar to

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have Multiple Sclerosis according to McDonald criteria. Beta-interferon is prescribed for them for the first time.

Exclusion criteria

Exclusion criteria: Patients who don't want to participate in this project. Patients that take vitamin C themselves. Patients who receive drugs other than beta-interferon for treatment of Multiple Sclerosis. Patients who have other autoimmune diseases or underlying diseases except Multiple Sclerosis.

Design outcomes

Primary

Measure	Time frame
Severity of fever. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of chills. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of body pain. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of weakness. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of flu like syndrome. Timepoint: The end of the first, second and third month. Method of measurement: Total scores of fever, chills, body pain, weakness.	—

Measure

Time frame

Severity of fever. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of chills. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of body pain. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of weakness. Timepoint: The end of the first, second and third month. Method of measurement: Scoring from 0 to 3 by asking the patient (zero means no symptoms, one means mild symptoms, two moderate and three severe symptoms).;Severity of flu like syndrome. Timepoint: The end of the first, second and third month. Method of measurement: Total scores of fever, chills, body pain, weakness.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Poursadeghfard

Shiraz University of Medical Sciences

poursadra@gmail.com+98 71 3230 5410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026